Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Journal of the American Academy of Dermatology 2024 Aug 23
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.
Related Questions
Would you switch to bimekizumab if a patient with psoriatic arthritis who is already on an IL-17 inhibitor has breakthrough skin or joint disease?
New comment
by at Hood River Dermatology ( December 5, 2024)
If it was a primary failure, what would be your choice of therapy?
Read more (2 Answers available)
21664
×
To continue please login or register
Register
or
Sign in